<DOC>
	<DOCNO>NCT02793388</DOCNO>
	<brief_summary>This randomize , control , open label trial ass effectiveness unsupervised versus supervise primaquine treatment patient uncomplicated malaria . In co-endemic region , risk P. vivax relapse follow treatment P. falciparum high . Hence patient infect either P. vivax P. falciparum include study . The study conduct Ethiopia . Participants enrol health centre provide recommended schizontocidal treatment plus primaquine radical cure either supervise unsupervised accord randomisation . Participants follow four month assess regular interval presence patent sub-patent malaria . The outcome study contribute improve treatment scheme uncomplicated malaria area .</brief_summary>
	<brief_title>A Trial Supervised Primaquine Use Ethiopia</brief_title>
	<detailed_description />
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<criteria>Fever ( axillary temperature ≥37.5⁰C ) history fever precede 48 hour Age &gt; 5 year Weight &gt; 5kg Written inform consent Living study area willing follow 4 month General danger sign symptom severe malaria ( Appendix 17.1 17.2 ) Anaemia , define Hb &lt; 8g/dl Pregnant woman determine Urine βHCG pregnancy test Breast feeding woman Known hypersensitivity drug give Living household individual enrol study last 14 day</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>